Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
P/E ratio for Geron Corporation (GERN)
P/E ratio as of 2023: -6.54
According to Geron Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.54. At the end of 2022 the company had a P/E ratio of -6.53.
P/E ratio history for Geron Corporation from 1996 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -6.54 |
| 2022 | -6.53 |
| 2021 | -3.30 |
| 2020 | -5.71 |
| 2019 | -4.07 |
| 2018 | -6.53 |
| 2017 | -10.27 |
| 2016 | -11.15 |
| 2015 | 16628.15 |
| 2014 | -13.99 |
| 2013 | -14.93 |
| 2012 | -2.45 |
| 2011 | -1.80 |
| 2010 | -4.30 |
| 2009 | -6.59 |
| 2008 | -5.56 |
| 2007 | -10.86 |
| 2006 | -17.48 |
| 2005 | -14.05 |
| 2004 | -4.20 |
| 2003 | -9.76 |
| 2002 | -2.47 |
| 2001 | -4.32 |
| 2000 | -6.64 |
| 1999 | -3.98 |
| 1998 | -10.89 |
| 1997 | -8.57 |
| 1996 | -6.03 |